Literature DB >> 21774717

Efficacy and safety of sirolimus in lymphangioleiomyomatosis.

Charles D Burger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21774717     DOI： 10.1056/NEJMc1106358

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Interleukin-6 mediates PSAT1 expression and serine metabolism in TSC2-deficient cells.

Authors:  Ji Wang; Harilaos Filippakis; Thomas Hougard; Heng Du; Chenyang Ye; Heng-Jia Liu; Long Zhang; Khadijah Hindi; Shefali Bagwe; Julie Nijmeh; John M Asara; Wei Shi; Souheil El-Chemaly; Elizabeth P Henske; Hilaire C Lam
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-28       Impact factor: 11.205

2.  A Novel Quantitative Computed Tomographic Analysis Suggests How Sirolimus Stabilizes Progressive Air Trapping in Lymphangioleiomyomatosis.

Authors:  Rahul G Argula; Maria Kokosi; Pechin Lo; Hyun J Kim; James G Ravenel; Cristopher Meyer; Jonathan Goldin; Hye-Seung Lee; Charlie Strange; Francis X McCormack
Journal:  Ann Am Thorac Soc       Date:  2016-03

3.  Soluble Immune-Related Proteins as New Candidate Serum Biomarkers for the Diagnosis and Progression of Lymphangioleiomyomatosis.

Authors:  Xuefei Liu; Yanping Xu; Xueying Wu; Yanpu Liu; Qiang Wu; Jialiang Wu; Henghui Zhang; Min Zhou; Jieming Qu
Journal:  Front Immunol       Date:  2022-03-01       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.